Biotech venture group targets China investors; Australia OKs Kalydeco;

@FierceBiotech: ChemAxon extends pharma software streak with Schrödinger deal. Article | Follow @FierceBiotech

 @JohnCFierce: When does pursuing a clinical study become unethical? Roche needs to review that question in the wake of aleglitazar fiasco. More | Follow @JohnCFierce

@RyanMFierce: Over 7 years EU & industry pumping €22.6B into R&D, €4.8B in pharma, to spur economic activity. Is it enough? Release | Follow @RyanMFierce

 @EmilyMFierce: 5 lessons from @FierceBiotech's rebooted LinkedIn group. Editor's corner | Follow @EmilyMFierce

> The Dutch venture capital group Life Science Partners is setting up a new fund aimed at attracting investors in China willing to ante up for European biotechs. Story 

> Australian regulators have approved Vertex's ($VRTX) Kalydeco for cystic fibrosis. Release

> UCB nabbed access to an antibody in Wilex's preclinical portfolio originally obtained from UCB in 2009. UCB has the right to develop the antibodies from the program in any indication outside the field of oncology, while Wilex keeps the rights to develop them for cancer. Release

Pharma News

@FiercePharma: Pfizer's vaccine hope Prevenar 13 wins new EU nod in adults. Will it translate into big sales? Report | Follow @FiercePharma

 @EricPFierce: Hikma ups doxycycline capacity as it brings production back at NJ plant that got FDA warning letter. ICYMI | Follow @EricPFierce

 @CarlyHFierce: Investors unhappy with plans from Russia's Pharmstandard to spin off OTC biz. May also buy Singapore-based Bever. Yesterday's story | Follow @CarlyHFierce

> GPhA: Patent settlements saved system $25.5B. More

> Pharma, FDA still lagging in post-marketing safety research. Report

> Vivus hooks up with Menarini to hawk ED pill Spedra in $121M deal. Article

Medical Device News

@FierceMedDev: Myriad sues Ambry over Dx gene patents. News | Follow @FierceMedDev

 @MarkHFierce: Are CT scans overused in children? A new study concludes that they are, boosting cancer risks. ICYMI yesterday | Follow @MarkHFierce

@DamianFierce: NeuroPace has hauled in another $18M to get its anti-epilepsy implant through the FDA process. Story | Follow @DamianFierce

> Blockbusters and bloodlettings: A look at 2013's hot M&A start. Special report

> Abbott rides next-gen Xience stent into Japan. Article

> Diaper device designed to flag babies' health problems. More

Biomarkers News

> Urine-based genetic test triumphs in trial. More

> Measuring electrical frequencies in brain could indicate Huntington's disease. Report

> U.K. Dx zeroes in on bladder cancer biomarkers in urine odor. Story

> Measuring electrical frequencies in brain could indicate Huntington's disease. Article

> Biomarker could guide decision on follow-up breast cancer treatment. News

Drug Delivery News

> Acorda grabs liquid and patch pain treatments for $8M-plus. Article

> BDSI hauls in $20M for pain film, addiction gel. More

> Oramed launches oral insulin safety trial. Report

> European injectable drug delivery market poised to soar. News

> Antibiotic-delivery strategies could cut back on side effects. Story

And Finally... A group of European cardiovascular experts say that drug R&D in the field has flagged badly, a problem that needs to be addressed by regulators. More

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.